Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares at an average price of $450.86, amounting to a total value of $1,803,440, significantly reducing her ownership by 96.85% to just 130 shares.
• United Therapeutics reported $6.41 EPS for the last quarter, missing analyst expectations of $6.80 EPS while achieving a quarterly revenue of $798.60 million, up 11.7% year-over-year.
• The company's stock has a market capitalization of $20.25 billion and an average price target of $449.57 from several research analysts, with a consensus rating of "Moderate Buy."

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the business's stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $450.86, for a total value of $1,803,440.00. Following the transaction, the chief executive officer owned 130 shares of the company's stock, valued at $58,611.80. This trade represents a 96.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $7.91 during trading hours on Wednesday, hitting $448.93. 540,933 shares of the company's stock traded hands, compared to its average volume of 595,131. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $459.48. The business has a fifty day moving average price of $362.60 and a 200-day moving average price of $320.98. The firm has a market capitalization of $20.25 billion, a P/E ratio of 17.52, a price-to-earnings-growth ratio of 6.91 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the firm earned $5.85 EPS. The firm's quarterly revenue was up 11.7% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently made changes to their positions in UTHR. UMB Bank n.a. increased its position in shares of United Therapeutics by 17.1% during the first quarter. UMB Bank n.a. now owns 1,289 shares of the biotechnology company's stock worth $397,000 after purchasing an additional 188 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of United Therapeutics by 20.3% during the first quarter. Farther Finance Advisors LLC now owns 456 shares of the biotechnology company's stock worth $140,000 after purchasing an additional 77 shares in the last quarter. Signet Financial Management LLC increased its position in shares of United Therapeutics by 0.7% in the 1st quarter. Signet Financial Management LLC now owns 10,895 shares of the biotechnology company's stock valued at $3,359,000 after acquiring an additional 79 shares during the period. SG Americas Securities LLC increased its position in shares of United Therapeutics by 210.9% in the 1st quarter. SG Americas Securities LLC now owns 10,085 shares of the biotechnology company's stock valued at $3,109,000 after acquiring an additional 6,841 shares during the period. Finally, Nepsis Inc. increased its position in shares of United Therapeutics by 6.7% in the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock valued at $18,057,000 after acquiring an additional 3,653 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the subject of several research analyst reports. Royal Bank Of Canada initiated coverage on shares of United Therapeutics in a research note on Friday, September 26th. They set an "outperform" rating and a $569.00 price target for the company. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research note on Wednesday, September 3rd. Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of United Therapeutics in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.